⚠️ FDA Failures and GLP-1 Compounding Risks

Tuesday, July 22, 2025 – “FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications. It highlights how temporary shortages of these drugs led to a…

💲 Tirzepatide: A Cost-Effective Path to Obesity Management

Thursday, July 17, 2025 – This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health outcomes and costs for patients, focusing on complications like cardiovascular events,…

⚖️ The History of Obesity

Sunday, July 13, 2025 – The provided text offers a comprehensive overview of how obesity has been understood and depicted across different historical periods, from ancient civilizations to the present day. It traces the evolution of obesity from being a symbol of wealth or a moral…

👨‍⚕️ AI-Driven Virtual Human for GP Obesity Training

Saturday, July 12, 2025 – This document presents a pilot feasibility study published in “Obesity Science & Practice” that investigates the effectiveness of an AI-driven Virtual Human (VH) intervention designed to enhance General Practitioner (GP) obesity education and communication skills. The research highlights the growing global…

👵 Ozempic Face: GLP-1 and Aesthetic Surgery

Friday, July 11, 2025 – This scholarly article from Aesthetic Surgery Journal Open Forum discusses the phenomenon of “Ozempic Face,” a term used to describe the accelerated facial aging and volume loss experienced by some patients undergoing rapid weight loss from GLP-1 receptor agonists like Ozempic.…